Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Lapatinib × 90 days × Clear all
NCT01589861 2026-04-21

PIKHER2

Institut Paoli-Calmettes

Phase 1/2 Terminated
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡